CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) Files An 8-K Other Events
ITEM 8.01 OTHER EVENTS.
On January 6, 2017, China Biologic Products, Inc. (the Company)
issued a press release announcing that its majority-owned
subsidiary Shandong Taibang Biological Products Co. Ltd. received
two approvals from the Shandong Provincial Health and Family
Planning Commission on December 30, 2016 to build a new plasma
collection station and a new branch collection facility,
respectively, in Shandong Province. A copy of the press release
is attached as Exhibit 99.1 to this current report and is
incorporated herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
|99.1||Press release issued by the Company dated January 6, 2017|
About CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO)
China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories. Its principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through approximately two subsidiaries, namely, Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co., Ltd., a plasma products company. Its products also include Human rabies immunoglobulin, Human tetanus immunoglobulin, Placenta polypeptide, Factor VIII and Human prothrombin complex concentrate. CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) Recent Trading Information
CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) closed its last trading session up +2.63 at 115.13 with 197,018 shares trading hands.